Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
July 13, 2017
Achaogen Appoints Dr. Karen Bernstein to its Board of Directors
SOUTH SAN FRANCISCO, Calif., July 13, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative ...
July 13, 2017
Advaxis Lead Immunotherapy Candidate Continues to Build Recognition Among Industry Leaders
PRINCETON, N.J.--(BUSINESS WIRE) -- Advaxis, Inc. (ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products based on its proprietary Lm-based ...
July 12, 2017
BioDelivery Sciences Signs Exclusive Agreement With Purdue Pharma (Canada) For The Licensing And Distribution Rights Of BELBUCA® In Canada
RALEIGH, N.C. and PICKERING, Ontario, July 12, 2017 /PRNewswire/ -- Today, BioDelivery Sciences International, Inc. (BDSI), a specialty pharmaceutical company with a focus in pain management ...
July 12, 2017
Oramed to Present at BIT'S 5th World Congress of Diabetes on July 13, 2017
JERUSALEM, July 12, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced ...
July 11, 2017
VBI Vaccines Announces Phase 3 Clinical Program for Sci-B-Vac(TM) Hepatitis B Vaccine
CAMBRIDGE, MASSACHUSETTS--(Marketwired - Jul 11, 2017) - VBI Vaccines Inc. (VBIV)(VBV.TO) ("VBI") announced today its plans for a global Phase 3 clinical program for Sci-B-Vac™, ...
July 11, 2017
Arena Pharmaceuticals Announces Proposed Public Offering of Common Stock
SAN DIEGO, July 11, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA) today announced that it intends to offer and sell, subject to market and other ...
July 11, 2017
Cytovia Inc, Immune Pharmaceuticals’ Oncology Subsidiary, Enters into a Definitive Agreement with Pint Pharma for the Licensing and Commercialization of Ceplene® in Latin America
NEW YORK--(BUSINESS WIRE) -- Cytovia Inc. (“Cytovia”) the oncology subsidiary of Immune Pharmaceuticals Inc. (NASDAQ: IMNP) ("Immune") announced today that it has entered into a licensing agreement ...
July 11, 2017
Arena Pharmaceuticals Reports Positive Topline Phase 2 Results for Ralinepag in Patients with Pulmonary Arterial Hypertension
SAN DIEGO, July 10, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA), today announced positive Phase 2 results for ralinepag, an investigational, long-acting, orally administered prostacyclin receptor ...
July 11, 2017
Aeglea BioTherapeutics Appoints James Wooldridge, M.D. as Chief Medical Officer
AUSTIN, Texas, July 10, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc., (AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino ...
July 11, 2017
Prometic Announces Positive Long Term Clinical Data on Ryplazym™ in Plasminogen Congenital Deficiency and Provides Regulatory Update
LAVAL, QC, July 11, 2017 /PRNewswire/ - Prometic Life Sciences Inc. (PLI.TO) (PFSCF) ("Prometic" or the "Corporation") today announced new long-term clinical data from its ...
July 11, 2017
DelMar Pharmaceuticals Appoints Saiid Zarrabian to the Board of Directors and Names Dr. Erich Mohr as Chairman
VANCOUVER, British Columbia and MENLO PARK, Calif., July 11, 2017 /PRNewswire/ -- DelMar Pharmaceuticals (DMPI) ("DelMar" and the "Company"), a biopharmaceutical company developing new cancer therapies, ...
July 11, 2017
Oramed Announces End-of-Phase 2 Meeting with FDA to Initiate Phase 3 Program
JERUSALEM, July 11, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced ...
July 11, 2017
Kitov Pharmaceuticals Announces Pricing of $3.5 Million Registered Direct Offering
TEL AVIV, Israel, July 11, 2017 /PRNewswire/ -- Kitov Pharmaceuticals (NASDAQ/TASE: KTOV), an innovative biopharmaceutical company focused on late-stage drug development, today announced that it has ...
July 10, 2017
Ignyta Receives FDA Orphan Drug Designation for Entrectinib for Treatment of NTRK Fusion-Positive Solid Tumors
SAN DIEGO--(BUSINESS WIRE) -- Ignyta, Inc. (RXDX), a biotechnology company focused on precision medicine in oncology, today announced that the U.S. Food and Drug Administration (FDA) ...
July 10, 2017
Reata Pharmaceuticals, Inc. Receives Orphan Drug Designation for Bardoxolone Methyl for the Treatment of Alport Syndrome
IRVING, Texas, July 10, 2017 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (RETA) (“Reata” or “the Company”), a clinical-stage biopharmaceutical company, today announced that the United ...
July 10, 2017
AC Immune Provides Seven Updates on its Pipeline and Technology at the Alzheimer's Association International Conference
Lausanne, Switzerland, July 10, 2017 - AC Immune SA (ACIU), a Swiss-based, clinical stage biopharmaceutical company focused on neurodegenerative diseases, today announced that seven updates ...
July 10, 2017
Rexahn Pharmaceuticals Receives Notice of Allowance for a New U.S. Patent Covering the Use of RX-3117
ROCKVILLE, Md., July 10, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment ...
July 7, 2017
Zealand Pharma files registration statement for proposed initial public offering of ADSs in the U.S.
Copenhagen, July 6, 2017 - Zealand Pharma ("Zealand" or the "Company") announces that it has today filed a Form F-1 Registration Statement for a proposed initial ...
July 6, 2017
Advaxis Announces Change in Leadership
PRINCETON, N.J.--(BUSINESS WIRE) -- Daniel J. O’Connor, chief executive officer, president and board member of Advaxis, Inc.(ADXS), a late-stage biotechnology company focused on the discovery, development ...
July 6, 2017
Mirati Therapeutics To Host Key Opinion Leader Breakfast On Immuno-oncology Combinations On July 11 In New York
SAN DIEGO, July 5, 2017 /PRNewswire/ -- Mirati Therapeutics, Inc. (MRTX), a clinical stage targeted oncology biotechnology company, announced today that they will host a ...
Page 106 of 117